ClinicalTrials.gg
RecruitingNCT07504588Updated Nov 20, 2026

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

A Phase 2 interventional study of Anti-VEGF Monoclonal Antibody and Bevacizumab in Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma and Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, sponsored by National Cancer Institute (NCI). Recruiting at 29 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know · 13 judgments

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 20, 2026Start date moved28 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Carcinoma, Endometrioid by National Cancer Institute (NCI) — 2 open to participants now, 7 under way, none of them phase 3. Carcinoma, Endometrioid · National Cancer Institute (NCI).

Planned enrollment
7th of 14
87 · median 84
Started
2026
the only one that year
Phase 2
9 of 14
2 open now
Registered
14th of 14
by date

Among the 14 studies in Carcinoma, Endometrioid by National Cancer Institute (NCI), this one is the 7th largest by planned enrollment, is the only one that started in 2026, is one of 9 in phase 2, and was the 14th registered.

Carcinoma, Endometrioid

46 studies on the registry are indexed under Carcinoma, Endometrioid; 11 are open to participants now.

Browse Carcinoma, Endometrioid studies →

Open to participants now

2 of the 14 studies in Carcinoma, Endometrioid by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 11 Carcinoma, Endometrioid studies recruiting now, 8 (73%) set no upper age limit and 3 (27%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Carcinoma, Endometrioid by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial response to platinum therapy (platinum-sensitive), that has progressed after poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor maintenance therapy (recurrent), and that has a mutation in the BRCA1 or BRCA2 genes or is homologous recombination deficient. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving sacituzumab govitecan and bevacizumab may kill more tumor cells than standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with recurrent platinum-sensitive ovarian cancers that have BRCA1/2 mutations or homologous recombination deficiency.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess the clinical activity of sacituzumab govitecan (sacituzumab govitecan-hziy [SG]) and bevacizumab (or an anti-VEGF antibody biosimilar) compared to standard of care carboplatin, pegylated liposomal doxorubicin hydrochloride (pegylated liposomal doxorubicin [PLD]) and bevacizumab (or an anti-VEGF antibody biosimilar), as measured by progression-free survival, in patients with platinum-sensitive ovarian cancer that has progressed while receiving first-line PARP inhibitor maintenance therapy.

SECONDARY OBJECTIVES:

I. To assess additional measures of clinical activity of SG and bevacizumab compared to standard of care carboplatin, PLD and bevacizumab in patients with recurrent platinum-sensitive ovarian cancer, as measured by the overall response rate, duration of response, and overall survival.

II. To assess the safety of SG and bevacizumab in patients with recurrent platinum-sensitive ovarian cancer.

III. To assess the effect of SG and bevacizumab on overall survival in recurrent platinum-sensitive ovarian cancer.

EXPLORATORY OBJECTIVES:

I. To correlate clinical activity of SG and bevacizumab with TROP2 expression and tumor-specific cell-free deoxyribonucleic acid (cfDNA).

II. To assess time to first subsequent therapy or death (TFST). III. To assess time to second subsequent therapy or death (TSST).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive carboplatin intravenously (IV) on day 1, PLD IV on day 1 (or gemcitabine IV on days 1 and 8), and bevacizumab (or anti-VEGF antibody biosimilar) IV on days 1 and 15 of each cycle. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. After 6-10 cycles, patients proceed to maintenance therapy.

ARM II: Patients receive SG IV over 1-3 hours on days 1 and 8 and bevacizumab (or anti-VEGF antibody biosimilar) IV on day 1 of each cycle. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. After 6-10 cycles, patients proceed to maintenance therapy.

MAINTENANCE: Patients receive bevacizumab (or anti-VEGF antibody biosimilar) IV on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients in Arm I also undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) at screening and all patients undergo computed tomography (CT) and/or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

03

Conditions studied

  • Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
  • Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma
  • Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma
  • Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma
  • Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma
  • Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must have histologic diagnosis of high grade serous or endometrioid epithelial ovarian cancer

    • Ovarian cancer = fallopian tube, ovarian, and primary peritoneal cancer
  • Disease must be platinum sensitive, as defined by progression documented ≥ 6 months (182 days) from the last receipt of platinum
  • Disease must have progressed during maintenance PARP inhibitor (PARPi) for advanced ovarian cancer. NO intervening therapies between progression on PARPi and study registration are permitted
  • Disease must be germline or somatic BRCA1 or BRCA2 mutated or homologous recombination deficiency test positive
  • Disease must be measurable or non-measurable as defined by (RECIST) version (v.) 1.1
  • Secondary or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted
  • No previous receipt of any topoisomerase-I inhibiting agents
  • No agents within 4 weeks of study registration
  • No current treatment with any other (non-study) cytotoxic chemotherapy, targeted therapy, biologic therapy, immunotherapy or endocrine therapy for the treatment of the disease under the current study
  • Last dose of PARP inhibitor treatment must be ≥ 3 weeks before study registration
  • Patients with treated are eligible if follow-up brain imaging 4 weeks after CNS-directed therapy shows no evidence of disease progression. Patients with brain metastases must have follow up imaging demonstrating no evidence of disease progression and that the disease is stable off of
  • Age ≥ 18
  • (ECOG) performance status of ≤ 2
  • Not pregnant and not nursing
  • (ANC) ≥ 1,500 cells/mm\^3
  • ≥ 100,000 cells/mm\^3
  • ≥ 9 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] ≥ 9 g/dl is acceptable)
  • (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula
  • Urinalysis with ≤ 1+ protein and/or urine protein \< 1.0 g/24 hours (hrs)
  • Total ≤ 1.5 x institutional (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled)
  • (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the functional classification. To be eligible for this trial, patients should be class 2B or better
  • No active infection requiring parenteral antibiotics
  • No non-healing wound, ulcer, or bone fracture
  • No current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or need for drainage nasogastric or gastrostomy tube
  • No bleeding within 28 days prior to registration
  • No uncontrolled hypertension, defined as systolic ≥ 160 mm Hg or diastolic ≥ 100 mm Hg
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the following exceptions:

    • Patients with grade 2 or lower neuropathy, any grade alopecia, well controlled hypertension, thyroid disease controlled with therapy, and history of thromboembolic disease on anticoagulation are eligible
    • Patients with laboratory-based grade 2 or higher adverse events (AEs) that meet the criteria outlined above are eligible
  • No major surgery within 3 weeks prior to study registration
  • Patients who underwent major surgery must have recovered adequately from any toxicity and/or complications from surgery prior to study registration
  • No strong inhibitors or inducers of UGT1A1
  • No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent(s) (or any of its )
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
87 participants (estimated)

Study arms

  • Active comparator
    Arm I (carboplatin, PLD, bevacizumab)

    Patients receive carboplatin IV on day 1, PLD IV on day 1 (or gemcitabine IV on days 1 and 8), and bevacizumab (or anti-VEGF antibody biosimilar) IV on days 1 and 15 of each cycle. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. After 6-10 cycles, patients proceed to maintenance therapy. MAINTENANCE: Patients receive bevacizumab (or anti-VEGF antibody biosimilar) IV on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA at screening and undergo CT and/or MRI and collection of blood samples throughout the trial.

    Biological: Anti-VEGF Monoclonal Antibody · Biological: Bevacizumab · Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Procedure: Echocardiography Test · Drug: Gemcitabine · Procedure: Magnetic Resonance Imaging · Procedure: Multigated Acquisition Scan · Drug: Pegylated Liposomal Doxorubicin Hydrochloride

  • Experimental
    Arm II (SG, bevacizumab)

    Patients receive SG IV over 1-3 hours on days 1 and 8 and bevacizumab (or anti-VEGF antibody biosimilar) IV on day 1 of each cycle. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. After 6-10 cycles, patients proceed to maintenance therapy. MAINTENANCE: Patients receive bevacizumab (or anti-VEGF antibody biosimilar) IV on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI and collection of blood samples throughout the trial.

    Biological: Anti-VEGF Monoclonal Antibody · Biological: Bevacizumab · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Biological: Sacituzumab Govitecan

Interventions

  • BiologicalAnti-VEGF Monoclonal Antibody

    Given IV

    Also known as: MoAb VEGF, Monoclonal Antibody Anti-VEGF

  • BiologicalBevacizumab

    Given IV

    Also known as: ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avegra, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-aveg, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-byva, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-nwgd, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, Byvasda, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, IBI 305, IBI-305, IBI305, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Jobevne, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • Given IV

    Also known as: Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureEchocardiography Test

    Undergo ECHO

    Also known as: EC, Echocardiography

  • Given IV

    Also known as: dFdC, dFdCyd, Difluorodeoxycytidine

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • DrugLiposomal doxorubicinStudies of Liposomal doxorubicinLiposomal doxorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Doxorubicin Liposomal, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99

  • Given IV

    Also known as: hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    The primary analysis will compare progression-free survival between Arm II and Arm I using a stratified log-rank test. The corresponding hazard ratio will be estimated from a stratified Cox regression model. The treatment hazard ratio estimate and its 95% confidence interval will be estimated using proportional hazards models specified to be consistent with the logrank tests.

    Time frame: From randomization to either progressive disease or death from any cause, assessed up to 5 years

Secondary outcomes

  1. Objective response rate (ORR)

    The ORR is the percentage of evaluable patients who achieve a complete response (CR) or partial response (PR) within 12 months of starting maintenance therapy. The analysis will be based on physician-assessed responses according to Response Evaluation Criteria in Solid Tumors 1.1 criteria. Comparisons of ORR between the experimental and reference groups will use a multivariable logistic regression model, stratified by the randomization factors, to estimate the odds ratio. A 95% Jeffries confidence interval will also be calculated for the ORR in each treatment arm.

    Time frame: Within 12 months of starting maintenance therapy

  2. Duration of response (DOR)

    DOR will be visualized using Kaplan-Meier curves, and the treatment groups will be compared with a stratified log-rank test. A stratified Cox proportional hazards model will be used to estimate the hazard ratio for progression or death between the groups.

    Time frame: From the first documented response (CR or PR) until disease progression or death, assessed up to 5 years

  3. Incidence of adverse events

    The nature, frequency, and degree of toxicity will be tabulated at the System Organ Class and adverse event-specific term levels using Common Terminology Criteria for Adverse Events version 5.0. Each patient will be represented according to the maximum grade observed for each term. Tabulations will show the number and percentage of patients by maximum grade, within the treatment group received, regardless of the randomized treatment assignment.

    Time frame: Up to 5 years

  4. Overall survival

    Estimates of treatment effect will be interpreted descriptively with associated confidence intervals, without formal hypothesis testing.

    Time frame: From randomization to death from any cause, assessed up to 5 years

Other outcomes

  1. TROP2 expression

    TROP2 expression will be correlated with clinical activity of sacituzumab govitecan (SG) and bevacizumab to assess how the clinical effect of the randomized treatment is modified by TROP2 expression. Will formally test the interaction between the biomarker and the treatment assignment to assess whether this is a predictive biomarker. A logistic regression model will be used to test the treatment-by-TROP2 interaction on the odds of achieving a response. The odds ratio for the treatment effect will be estimated within each TROP2 subgroup. A Cox proportional hazards model will be fitted with main effects for treatment, TROP2 status, and a treatment-by-TROP2 interaction term. A statistically significant interaction term would suggest TROP2 is a predictive biomarker. The treatment effect will be estimated and displayed on a forest plot for TROP2-high and TROP2-low subgroups. Kaplan-Meier curves for PFS will be plotted for each treatment arm within each TROP2 subgroup.

    Time frame: Up to 5 years

  2. Cell-free deoxyribonucleic acid (cfDNA)

    cfDNA expression will be correlated with clinical activity of SG and bevacizumab to assess how the clinical effect of the randomized treatment is modified by cfDNA expression. Will formally test the interaction between the biomarker and the treatment assignment to assess whether this is a predictive biomarker.

    Time frame: Up to 5 years

  3. Time to first subsequent therapy or death (TFST)

    TFST distributions by randomized treatment assignment in the intent to treat population will be visualized using Kaplan-Meier curves. The effect of treatment assignment on TFST will be estimated using a Cox proportional hazards model, stratified by the randomization factors. Hazard ratio estimates and 95% confidence intervals will be reported to quantify the treatment effect. Treatment effects within strata will be presented in a forest plot.

    Time frame: From randomization to the earliest occurrence of either first subsequent therapy or death, assessed up to 5 years

  4. Time to second subsequent therapy or death (TSST)

    TSST distributions by randomized treatment assignment in the intent to treat population will be visualized using Kaplan-Meier curves. The effect of treatment assignment on TSST will be estimated using a Cox proportional hazards model, stratified by the randomization factors. Hazard ratio estimates and 95% confidence intervals will be reported to quantify the treatment effect. Treatment effects within strata will be presented in a forest plot.

    Time frame: From randomization to the earliest occurrence of either second subsequent therapy or death, assessed up to 5 years

07

Study locations

29 of 29 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

13 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Apr 2029, 30 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jun 2027 → Sep 2026, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 1, 2026
StartActual
Sep 24, 2026was Jun 2027
Primary completionEst.
Apr 12, 2029
CompletionEst.
Apr 12, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
28 sites added
Show 28 added (28 United States)
  • Kootenai Health - Coeur d'Alene · Coeur d'Alene, United States
  • Kootenai Clinic Cancer Services - Post Falls · Post Falls, United States
  • Kootenai Clinic Cancer Services - Sandpoint · Sandpoint, United States
  • Highlands Oncology Group - Fayetteville · Fayetteville, United States
  • Highlands Oncology Group - Rogers · Rogers, United States
  • Highlands Oncology Group · Springdale, United States
  • Billings Clinic Cancer Center · Billings, United States
  • Community Medical Center · Missoula, United States
  • Benefis Sletten Cancer Institute · Great Falls, United States
  • Mercy Hospital · Cedar Rapids, United States
  • Oncology Associates at Mercy Medical Center · Cedar Rapids, United States
  • Logan Health Medical Center · Kalispell, United States
  • Carle at The Riverfront · Danville, United States
  • Carle Physician Group-Effingham · Effingham, United States
  • Carle Physician Group-Mattoon/Charleston · Mattoon, United States
  • Carle BroMenn Medical Center · Normal, United States
  • Carle Cancer Institute Normal · Normal, United States
  • Carle Cancer Center · Urbana, United States
  • Community Hospital of Anaconda · Anaconda, United States
  • University of Oklahoma Health Sciences Center · Oklahoma City, United States
  • Rutgers Cancer Institute of New Jersey · New Brunswick, United States
  • Monmouth Medical Center · Long Branch, United States
  • Our Lady of the Lake Physician Group · Baton Rouge, United States
  • Our Lady of the Lake Medical Oncology · Baton Rouge, United States
  • Community Medical Center · Toms River, United States
  • University of Virginia Cancer Center · Charlottesville, United States
  • Goshen Center for Cancer Care · Goshen, United States
  • Bozeman Health Deaconess Hospital · Bozeman, United States
across 13 updates, Sep 28, 2026 – Nov 20, 2026
Start date
Jun 1, 2027→Sep 24, 2026 (actual)
Sep 29, 2026
Show all 13 updates
  1. Nov 20, 2026
    1 site added
    Show site
    • Bozeman Health Deaconess Hospital · Bozeman, United States
  2. Nov 19, 2026
    1 site added
    Show site
    • Goshen Center for Cancer Care · Goshen, United States
  3. Nov 18, 2026
    4 sites added
    Show 4 added (4 United States)
    • Our Lady of the Lake Physician Group · Baton Rouge, United States
    • Our Lady of the Lake Medical Oncology · Baton Rouge, United States
    • Community Medical Center · Toms River, United States
    • University of Virginia Cancer Center · Charlottesville, United States
  4. Nov 9, 2026
    1 site added
    Show site
    • Monmouth Medical Center · Long Branch, United States
  5. Nov 5, 2026
    1 site added
    Show site
    • Rutgers Cancer Institute of New Jersey · New Brunswick, United States
  6. Nov 4, 2026
    2 sites added
    Show 2 added (2 United States)
    • Community Hospital of Anaconda · Anaconda, United States
    • University of Oklahoma Health Sciences Center · Oklahoma City, United States
  7. Oct 29, 2026
    6 sites added
    Show 6 added (6 United States)
    • Carle at The Riverfront · Danville, United States
    • Carle Physician Group-Effingham · Effingham, United States
    • Carle Physician Group-Mattoon/Charleston · Mattoon, United States
    • Carle BroMenn Medical Center · Normal, United States
    • Carle Cancer Institute Normal · Normal, United States
    • Carle Cancer Center · Urbana, United States
  8. Oct 20, 2026
    1 site added
    Show site
    • Logan Health Medical Center · Kalispell, United States
  9. Oct 19, 2026
    2 sites added
    Show 2 added (2 United States)
    • Mercy Hospital · Cedar Rapids, United States
    • Oncology Associates at Mercy Medical Center · Cedar Rapids, United States
  10. Oct 16, 2026
    1 site added
    Show site
    • Benefis Sletten Cancer Institute · Great Falls, United States
  11. Oct 5, 2026
    2 sites added
    Show 2 added (2 United States)
    • Billings Clinic Cancer Center · Billings, United States
    • Community Medical Center · Missoula, United States
  12. Sep 29, 2026
    3 sites added
    Show 3 added (3 United States)
    • Highlands Oncology Group - Fayetteville · Fayetteville, United States
    • Highlands Oncology Group - Rogers · Rogers, United States
    • Highlands Oncology Group · Springdale, United States
    Start date Jun 1, 2027→Sep 24, 2026 (now actual)
  13. Sep 28, 2026
    3 sites added
    Show 3 added (3 United States)
    • Kootenai Health - Coeur d'Alene · Coeur d'Alene, United States
    • Kootenai Clinic Cancer Services - Post Falls · Post Falls, United States
    • Kootenai Clinic Cancer Services - Sandpoint · Sandpoint, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07504588
Responsible party
Sponsor
First posted
Apr 1, 2026
Start date
Sep 24, 2026
Primary completion
Apr 12, 2029 (estimated)
Completion
Apr 12, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Rebecca L Porter
principal investigator · NRG Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion